• News
  • SAN DIEGO
  • BioTech

Ligand inks deal with Omthera Pharma

San Diego-based Ligand Pharmaceuticals (Nasdaq: LGND) has signed a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca (NYSE: AZN), for the development of products to treat dyslipidemia, a high concentration of cholestorol, fat or other lipids in the blood.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11085 N. Torrey Pines Rd. Ste., 300
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
46.99
  -0.62  
- 1.30%
551,801,000
80.42
41.83

Insider Trade Data

Date Insider Shares Type Value
08/15/2014 Higgins, John L 1,000 Purchase $54,970
08/15/2014 Higgins, John L 1,000 Purchase $54,970
06/09/2014 Herman, Melanie J 1,100 Sell $76,648
06/09/2014 Herman, Melanie J 1,100 Sell $76,648
06/09/2014 Herman, Melanie J 1,100 Exchange $13,741

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
Subscribe Today!